Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Akamai Technologies Q1 2026 Earnings Call - $1.8 Billion AI Infrastructure Win Signals Shift to Distributed Inference Grid
Akamai Technologies delivered a strong Q1 2026, driven by a record $1.8 billion seven-year cloud infrastructure deal with a frontier AI model company. This landmark contract, alongside a $200 million ...
- Akamai secured a historic $1.8 billion, seven-year cloud infrastructure services contract with a leading frontier AI model company, marking the largest deal in the firm’s history.
- Cloud Infrastructure Services (CIS) revenue surged 40% year-over-year to $95 million in Q1, reflecting rapid adoption of Akamai’s distributed AI inference platform.
- Total Q1 revenue reached $1.074 billion, up 6% year-over-year, with security revenue growing 11% and delivery revenue declining 7% due to the Edgio transaction.
- +7 more takeaways
Alta Equipment Group Q1 2026 Earnings Call - Q1 Weakness Masks Strong Booking Inflection and Margin Recovery
Alta Equipment Group reported a disappointing Q1 2026, with revenues falling 3% year-over-year to $410.5 million and adjusted EBITDA coming in at $28.1 million. The miss was driven by a perfect storm ...
- Q1 revenues fell 3% year-over-year to $410.5 million, with adjusted EBITDA of $28.1 million missing internal expectations due to seasonal headwinds and tax-driven pull-forward sales in Q4 2025.
- Material Handling segment revenues declined 4.7% to $150.5 million, driven by soft used equipment sales, but bookings surged to their strongest level since June 2023, signaling a clear inflection point.
- Construction Equipment revenues remained flat at $244.3 million, supported by strong quoting activity and fully funded state and federal infrastructure spending, despite a delayed start to the seasonal construction cycle.
- +7 more takeaways
Globus Medical Q1 2026 Earnings Call - Margin Expansion and EPS Guidance Hike
Globus Medical delivered a robust Q1 2026, with revenue rising 27% to $759.9 million and non-GAAP EPS jumping 64.7% to $1.12. The company is clearly executing on its integration and margin expansion p...
- Q1 2026 revenue reached $759.9 million, a 27% increase year-over-year, driven by strong performance across US Spine, International Spine, and Trauma.
- Non-GAAP EPS surged 64.7% to $1.12, beating expectations and prompting management to raise full-year EPS guidance to $4.70-$4.80.
- Adjusted gross profit margin remained resilient at 69.2% despite a typical seasonal Q1 decline, highlighting successful manufacturing and supply chain synergies.
- +7 more takeaways
Oportun Financial Corporation Q1 2026 Earnings Call - New CEO Reiterates Full-Year Guidance Amid Tight Credit Posture
Oportun Financial reported a cautious Q1 2026, marked by an 11% decline in originations and a 12.65% annualized net charge-off rate, the midpoint of guidance. The new CEO, Doug Bland, arrived less tha...
- New CEO Doug Bland, who joined less than three weeks ago, chose to reiterate the full-year 2026 guidance rather than announce a new strategy, citing the need for a deeper assessment of the business foundation.
- Originations declined 11% year-over-year in Q1, driven by seasonality and a strategic shift toward returning members, who now account for 79% of originations compared to 63% in the prior year quarter.
- The annualized net charge-off rate came in at 12.65%, the midpoint of guidance, but management expects this to be the highest rate of 2026, with delinquency rates improving sequentially.
- +10 more takeaways
Covista Q3 2026 Earnings Call - Chamberlain Returns to Growth, Guidance Raised Amid Structural Healthcare Labor Shortage
Covista delivered a strong third quarter, driven by enrollment momentum across Chamberlain, Walden, and its medical and veterinary segments. Chamberlain returned to positive total enrollment growth ah...
- Covista surpassed 100,000 total students with 11 consecutive quarters of growth, marking a structural inflection point in its national healthcare education platform.
- Chamberlain returned to positive total enrollment growth (0.5%) ahead of plan after fixing marketing effectiveness and funnel conversion issues, with application volumes and conversion rates normalizing to historical levels.
- Walden University set a new enrollment record with 12.3% growth to over 54,000 students, driven by broad-based program gains and improved first-to-second semester retention.
- +7 more takeaways
Inogen Q1 2026 Earnings Call - International Growth and Pipeline Expansion Offset U.S. Rental Pressure
Inogen delivered Q1 2026 revenue of $85.1 million, beating expectations as international sales surged 18% year-over-year, more than compensating for a 5% decline in U.S. sales. The company is navigati...
- Total revenue reached $85.1 million, up 3.4% year-over-year, beating management expectations.
- International sales surged 18% year-over-year to $37.7 million, driven by strong execution in Eastern Europe, Latin America, and Asia Pacific.
- U.S. sales declined 5% to $34.7 million, pressured by a structural shift where 60% of new long-term patients now start on POCs, hurting direct-to-consumer and rental channels.
- +10 more takeaways
ESCO Technologies Q2 2026 Earnings Call - Record Backlog and Megger Acquisition Drive Guiding Increase
ESCO Technologies delivered another exceptional quarter in Q2 2026, reporting a 42% surge in orders and a 13% organic revenue increase. The results were fueled by robust demand across all three segmen...
- Record backlog confirmed as orders surged 42% year-over-year, driven by double-digit organic growth across all three segments.
- Full-year 2026 adjusted EPS guidance raised to $8.00-$8.25, representing 33%-37% growth over fiscal 2025.
- Megger Group acquisition on track for Q1 FY2027 close, with early integration planning underway alongside Doble.
- +7 more takeaways
Nu Skin Enterprises Q1 2026 Earnings Call - Prysm iO Adoption and Margin Pressures Define Near-Term Outlook
Nu Skin Enterprises reported Q1 2026 revenue of $320.6 million, landing within guidance, while adjusted EPS of $0.14 matched expectations. The results highlight a company in transition, balancing earl...
- Q1 2026 revenue came in at $320.6 million, within the guidance range, including a 1% favorable foreign currency impact.
- Adjusted EPS was $0.14, in line with expectations, while GAAP EPS was $0.04, excluding costs related to the wind-down of the BeautyBio business.
- Adjusted gross margin held steady at 67.9%, with core Nu Skin gross margin improving 20 basis points to 76.9% year-over-year.
- +12 more takeaways
Artivion Q1 2026 Earnings Call - Endospan Acquisition and AMDS Ramp Challenges
Artivion delivered a solid Q1 2026 with constant currency revenue growth of 12% and adjusted EBITDA growth of 26%, driven by strong On-X valve and tissue processing performance. However, stent graft g...
- Artivion reported Q1 2026 constant currency revenue of $116.3 million, up 12% year-over-year, with adjusted EBITDA of $22.1 million, up 26% year-over-year.
- Stent graft revenue grew 10% constant currency, but missed expectations due to soft international demand (especially Middle East) and slower U.S. AMDS starter set sales.
- On-X aortic valve revenue surged 17% constant currency, driven by global market share gains and early traction in a new $100 million U.S. market opportunity for patients under 65.
- +7 more takeaways
Tandem Diabetes Care Q1 2026 Earnings Call - PayGo Pharmacy Transition and Margin Expansion Drive Momentum
Tandem Diabetes Care delivered a strong first quarter in 2026, recording record pump shipments of over 29,000 and $247 million in sales. The company is actively reshaping its U.S. business model throu...
- Record Q1 2026 pump shipments exceeded 29,000 globally, with U.S. shipments growing approximately 10% year-over-year to over 19,000 units.
- Tandem launched its Pay-As-You-Go (PAYG) pharmacy channel in the U.S., achieving approximately 40% formulary coverage within weeks of implementation in March 2026.
- U.S. sales reached $161 million, up 7% year-over-year, despite a modest headwind from PAYG adoption and minor infusion set supplier shortages.
- +7 more takeaways